Skip to content
RDL
Network
Ekosistem
Uygulama değiştir
EN
Hakkımızda
SSS
Giriş yap
Başla
Antithrombotic therapy in chronic liver disease: to clot or not to clot — Peter Calvert (2021) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Antithrombotic therapy in chronic liver disease: to clot or not to clot
Shared by
Professor Gregory Lip
University of Liverpool
Antithrombotic therapy in chronic liver disease: to clot or not to clot
Article
2021
en
Authors
PC
Peter Calvert
DG
Dhiraj Gupta
Professor Gregory Lip
University of Liverpool
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Editorial Material
2021
Atrial fibrillation in the presence of chronic kidney disease: Toablate or not to ablate
Wern Yew Ding
,
Dhiraj Gupta
,
Christopher F. Wong
,
Professor Gregory Lip
Article
2018
Su1505 - Liver Fat is not Associated with Prevalent or Incident Chronic Kidney Disease after Accounting for Obesity
Robert M. Wilechansky
,
Alison Pedley
,
Udo Hoffmann
,
Emelia Benjamin
,
Michelle T. Long
Article
1998
Antithrombotic Therapy for Venous Thromboembolic Disease
Thomas M. Hyers
,
Giancarlo Agnelli
,
Russell D. Hull
,
John G. Weg
,
Timothy A. Morris
,
Michel Samama
,
Victor F. Tapson
Letter
2022
Antithrombotic Therapy in Atrial Fibrillation and Coronary Artery Disease
Ying X. Gue
,
Diana A. Gorog
,
Professor Gregory Lip
Article
2016
Outcome of Asunaprevir/Daclatasvir Combination Therapy for Chronic Liver Disease Type C
Satoru Hagiwara
,
Naoshi Nishida
,
Tomohiro Watanabe
,
Toshiharu Sakurai
,
Hiroshi Ida
,
Yasunori Minami
,
Masahiro Takita
,
Tomohiro Minami
,
Mina Iwanishi
,
Hirokazu Chishina
,
Kazuomi Ueshima
,
Yoriaki Komeda
,
Tadaaki Arizumi
,
Masatoshi Kudo
Discussion(0)
No comments yet. Be the first to comment.